OpenAlex · Aktualisierung stündlich · Letzte Aktualisierung: 03.05.2026, 14:03

Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.

Erythropoietin pretreatment for myocardial protection in perioperative period of infant congenital heart disease operation

2018·0 Zitationen·Zhongguo xiaoer jijiu yixue
Volltext beim Verlag öffnen

0

Zitationen

2

Autoren

2018

Jahr

Abstract

Objective To study the effect of erythropoietin(EPO)pretreatment on myocardial protection in perioperative period of infant congenital heart disease operation and explore its underlying mechanism. Methods All the 80 patients who were suffered from non-cyanotic congenital heart disease undergone cardiopulmonary bypass in open heart operation were selected from Shengjing Hospital of China Medical University cardiac surgery ward from April 2014 to January 2017.The patients were randomly divided into A, B, C three groups according to blocked randomization method.Group A patients were treated with subcutaneous injection of EPO 150 IU/kg 12 hours before operation, group B patients were treated with subcutaneous injection of EPO 300 IU/kg 12 hours before operation, patients in group C(control group) had no treatment.All patients were detected myocardial zymetology after admission to hospital as well as 24 h, 48 h, 72 h after operation.HSP70, ERK1/2 mRNA and protein expression in right auricle were detected by qRT-PCR and Western blot method, respectively. Results At each time point after operation, myocardial zymetology were significantly lower in group A and B compared with group C, the index of myocardial zymetology in group A were lower than that in group B(P<0.05). The expressions of HSP70, ERK1/2 mRNA and protein were significantly up-regulated in group A and B compared to the control group(P<0.05). The expressions of HSP70, ERK1/2 mRNA and protein in group A were significantly higher than those in group B(P< 0.05). Conclusion EPO pretreatment has a positive effect on the myocardial protection during cardiopulmonary bypass.EPO may act a role of endogenous myocardial protection through up-regulation of the expressions of HSP70 and ERK1/2.The dosage of 150 IU/kg EPO is more significant on the effect of myocardial protection. Key words: Erythropoietin; Immature myocardium; HSP70; ERK1/2; Myocardial protection

Ähnliche Arbeiten

Autoren

Institutionen

Themen

Artificial Intelligence in Healthcare and Education
Volltext beim Verlag öffnen